RxDoctor Payments Data

Nicole Greene, APRN

Gerontology · Draper, UTNPI 1538830989

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 42.5% of the total.

$405in general payments, 2019–2025

Across 21 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$172
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$44
  • Novo Nordisk$33
  • Lundbeck LLC$29
  • Acadia Pharmaceuticals Inc$28
  • Vertex$25
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$405 in reported general payments places this provider in the 60th percentile of 26 gerontology providers in Utah.

See all gerontology providers in Utah

Medicare billing

Part B allowed, 2024
$81,052
Medicare patients
174
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$28,625
XareltoRivaroxaban38$20,793
OzempicSemaglutide16$16,182
LinzessLinaclotide14$7,167
Aimovig AutoinjectorErenumab-Aooe12$5,663
MyrbetriqMirabegron11$4,955
Duloxetine Hcl65$3,870
Methenamine Hippurate57$3,079
Levothyroxine Sodium197$2,210
Sertraline Hcl120$1,606
Lamotrigine OdtLamotrigine12$1,485
Trazodone Hcl167$1,478
Bupropion XlBupropion Hcl30$1,374
Xigduo XrDapaglifloz Propaned/Metformin11$1,345
Aripiprazole16$1,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$33$16,18216 claims
AbbVieLinzess$172$7,16714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 26 gerontology providers in Utah.

Other gerontology in Draper

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →